Avicanna (TSE:AVCN) has released an update.
Avicanna Inc., a leader in cannabinoid-based biopharmaceuticals, has successfully elected its management’s nominees as directors and reappointed its auditors during the Annual General Meeting. The company continues to advance in the medical cannabis and pharmaceutical markets, recently expanding its RHO Phyto medical brand internationally and securing approval for its pharmaceutical drug, Trunerox, in Colombia.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
